Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. We established 12 PDXs from BRAF inhibitor-progressed melanoma patients. Following expansion, PDXs were analyzed using targeted sequencing and reverse-phas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-04, Vol.22 (7), p.1592-1602
Hauptverfasser:	Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia A, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L, Xu, Xiaowei, Karakousis, Giorgos C, Mills, Gordon B, Lu, Yiling, Ahmed, Tamer A, Poulikakos, Poulikos I, Caponigro, Giordano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M, Weeraratna, Ashani T, Herlyn, Meenhard
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cluster Analysis Disease Models, Animal Disease Progression Drug Evaluation, Preclinical Drug Resistance, Neoplasm Gene Amplification Gene Expression Profiling Humans Melanoma - drug therapy Melanoma - genetics Melanoma - metabolism Melanoma - pathology Mice Mitogen-Activated Protein Kinases - metabolism Molecular Targeted Therapy Mutation Phosphatidylinositol 3-Kinases - metabolism Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacology Proteomics Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Proto-Oncogene Proteins c-met - genetics Proto-Oncogene Proteins c-met - metabolism Signal Transduction - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!